Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma is a research paper published in Cancer Immunology Immunotherapy (2022). On theSindex it has a DataRank of 0. It has been cited 5 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01FD006108
National Institutes of Health
Grant: 1TL1TR001875-01
NRSA Training Core
National Institutes of Health
Grant: KL2TR001874
Spanish Ministerio de Economía y Competitividad, European Development Regional Fund
Grant: SAF-2016-80535-R
Fundação para a Ciência e a Tecnologia
Grant: SFRH/ BD/75738/2011
National Center for Advancing Translational Sciences
Grant: UL1TR001873
NCATS NIH HHS
Grant: TL1 TR001875
NIAMS NIH HHS
Grant: P30 AR069632
NCI NIH HHS
Grant: R01 CA260375
NCI NIH HHS
Grant: UH3 CA218149
National Institutes of Health
Grant: 1R01CA260375-01
Applying pathomics to establish a biosignature for aggressive skin melanoma.
National Institutes of Health
Grant: 5KL2TR001874-02
Institutional Career Development Core
National Institutes of Health
Grant: 5R01FD006108-03
Ph1 Study of T-Vec given endoscopically for advanced pancreatic cancer IN 17248 (11/21/2016)
National Institutes of Health
Grant: 3UL1TR001873-07S1
Clinical and Translational Science Award
Swim Across America
Amgen-CUMC-MRA (Melanoma Research Alliance) Established Investigator Academic-Industry Partnership Award
FWCI
0.47
Citation Percentile
0.6%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals